Colgate Palmolive's Q4 earnings show a notable increase, driven by a combination of strategic pricing and robust product demand.

HSBC maintains a Hold rating for Colgate with a revised price target of ₹2150, after the company reported better-than-expected Q4 sales due to a mix of volume and value growth. While premium product traction contributes to growth and supports premiumization, the overall outlook remains unchanged following a minor upgrade in EBITDA.

Kotak Securities has retained a cautious stance on Colgate-Palmolive, setting a target price of INR 2025. The decision is attributed to a projected 9% revenue growth, yet concerns over margin pressures persist due to factors like a decline in gross margins, increased advertising expenses, and duty structure adjustments.

Goldman Sachs has retained its pessimistic outlook for Colgate Palmolive India, but has increased their forecast price to INR 2,000, raising it from INR 1,925. This suggests a continued cautious stance towards the company.

Nomura recently increased its recommendation for Colgate-Palmolive India to 'buy', predicting a target price of ₹2,500 due to enhanced volume growth and premiumization. Although other analysts have suggested 'sell' from Citi and 'reduce' from Kotak, the stock has managed a 3% rise this year, ending at ₹2,156.9.

Jefferies continues to recommend buying Colgate stocks, predicting a price of INR 2600. This optimism stems from the robust demand in the oral care segment and anticipation of strong EPS growth in FY27 due to better financial conditions following some challenging years.

Colgate's Q4 sales exceeded forecasts, leading to the announcement of a significant ₹24 dividend payout to its shareholders. The company's impressive performance underscores its strong financial health.

Despite a steady performance, Colgate-Palmolive India's Q4 earnings remained unchanged due to the impact of GST charges. The company is undeterred and anticipates a positive outlook for future quarters.

The BSE 100 undergoes changes with the addition of Paytm, Ashok Leyland, and CG Power, while Ambuja, Tube Investments, and Colgate-Palmolive are now no longer part of this index.

Three companies - Ambuja Cements, Tube Investments, and Colgate - have decided to leave the BSE 100 index, indicating a potential shakeup in the top-tier stock market listings.

Colgate-Palmolive India has announced that the record date for its final dividend of the fiscal year 2025-26 is set for May 29, 2026. Shareholders who are on record by this date will be eligible to receive the dividend if it gets approved.

Colgate Palmolive India's Q4 sales have increased by 9% year-over-year, reaching INR 1,583 crores. The company also announced an interim dividend of INR 24 per share for the fiscal year 2026, totaling INR 48, payable on June 17, 2026.

Colgate's Q4 sales increased by 9% due to an emphasis on premium oral care products, strategic advertising, and higher urban demand. However, the company's FY2026 net profit was affected by the GST impact and a challenging first half of the year.

Colgate's Q4 earnings could be impacted by tightening margins, causing unease among investors due to potential profitability concerns.

Colgate-Palmolive's Q1 sales have grown by 8.4% in Q1, with organic sales increasing by 2.9%. The company reported a base business EPS rise of 7%, accompanied by a significant surge of 28% in free cash flow year over year. Furthermore, the global toothpaste market share has risen, indicating a strong start to the fiscal year.

Colgate's impressive 7% increase significantly bolstered the overall performance of the Fast-Moving Consumer Goods (FMCG) sector, indicating a positive trend for related companies.